Is It Time To Reassess Phibro Animal Health (PAHC) After The Recent Share Price Pullback

• Investors may be wondering if Phibro Animal Health at around US$43.16 is still offering value after a strong run, or if the easy gains are behind it.
• The stock has pulled back 18.8% over the last week and 22.5% over the last month, yet it still shows a 15.7% gain year to date and a 96.6% return over the past year.
• These sharp moves are drawing attention back to what is already priced into Phibro Animal Health and how much of its story is reflected in the current share price. Ongoing interest in the stock means many investors are using this volatility as a prompt to reassess what they are really paying for.
• Right now, Phibro Animal Health has a valuation score of 2 out of 6. The next sections will look at how traditional methods like P/E, multiples and discounted cash flow frame that score, and why there might be an even better way to think about value by the end of this article.

Phibro Animal Health scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Phibro Animal Health Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow (DCF) model estimates what a company could be worth today by projecting its future cash flows and discounting them back to a present value. For Phibro Animal Health, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in $.

The latest twelve month free cash flow is reported at about $13.0 million. Analysts provide explicit forecasts for several years, including projected free cash flow of $135.65 million in 2028, with further projections beyond that point extrapolated by Simply Wall St rather than based on additional analyst estimates.

Taking all these projected cash flows and discounting them, the DCF model arrives at an estimated intrinsic value of about $118.57 per share. Compared with the recent share price of around $43.16, this implies the stock is trading at roughly a 63.6% discount to that DCF estimate. This indicates the model outputs a valuation that is higher than the recent share price, assuming the projections used in the model are met.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Phibro Animal Health is undervalued by 63.6%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Phibro Animal Health.

Approach 2: Phibro Animal Health Price vs Earnings

For profitable companies, the P/E ratio is a useful way to think about value because it links what you pay for each share to the earnings that support it. A “normal” or “fair” P/E typically reflects what investors are willing to pay given their expectations for future growth and the level of risk they see in those earnings.

Phibro Animal Health currently trades on a P/E of 18.37x. That sits above the Pharmaceuticals industry average of 16.05x and above the peer average of 14.22x, which on simple comparisons can make the stock look more expensive than many industry peers.

Simply Wall St’s Fair Ratio for Phibro Animal Health is 17.59x. This is a proprietary estimate of what its P/E might be given factors such as earnings growth, industry, profit margins, market cap and specific risks. Because it incorporates these company level features, the Fair Ratio can be more informative than just lining the stock up against broad industry or peer averages that may have very different profiles.

Comparing the current P/E of 18.37x to the Fair Ratio of 17.59x suggests the stock is trading somewhat above that fair level, which points to it being overvalued on this metric.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Phibro Animal Health Narrative

Earlier it was mentioned that there is an even better way to think about valuation: Narratives. Narratives are simply your story about Phibro Animal Health linked to clear numbers like your fair value, revenue, earnings and margin assumptions, so you can see how that story compares with the current price.

On Simply Wall St’s Community page, Narratives let you connect a company’s qualitative story to a quantified forecast and a fair value, then compare that fair value with the live share price to help you decide whether you see the stock as priced above or below what your narrative suggests.

Because Narratives update when new information such as earnings guidance or research moves fair value assumptions, they stay current. If you think Phibro Animal Health justifies a fair value closer to US$62.0 or, at the other end of the range, US$38.0, you can base that view on explicit assumptions and see how it stacks up against where the stock is trading today.

For Phibro Animal Health, here are previews of two leading Phibro Animal Health Narratives to make comparison easier:

Start with a bullish version if you think the current pullback is just the market resetting expectations for a stock that still has room to run. Then compare it with a more cautious take that leans on tougher assumptions and lower implied returns.

🐂 Phibro Animal Health Bull Case

Fair value in this bullish narrative: US$48.50 per share.

Implied discount to that fair value at US$43.16: about 11.0%.

Revenue growth used in this narrative: 3.47% a year.

• Analysts in this camp link their view to raised price targets, a steady fair value of US$48.50 and earnings forecasts that build on the Zoetis medicated feed additive acquisition, ongoing Phibro Forward efficiency work and diversification into vaccines and nutritional specialties.
• The narrative assumes revenue of about US$1.5b and earnings of US$119.1m by 2028, with profit margins rising from 3.7% to 7.7% and the stock trading on a P/E of 14.6x, which is below the 19.0x industry P/E figure cited for the US Pharmaceuticals sector.
• Supporters see room for balanced returns if revenue, margin expansion and capital allocation all track these assumptions. They still flag regulatory, environmental and execution risks that could pull the stock away from the implied fair value.

🐻 Phibro Animal Health Bear Case

Fair value in this cautious narrative: US$38.00 per share.

Implied premium to that fair value at US$43.16: about 13.6%.

Revenue growth used in this narrative: 3.48% a year.

• The bearish narrative leans on a fair value of US$38.00 that lines up with the lower end of analyst targets and focuses on execution risks around margin guidance, earnings per share targets and the ability to sustain growth in a market facing regulation and changing consumer habits.
• It builds in revenue of about US$1.6b and earnings of US$156.7m by 2029, with margins rising from 6.3% to 9.7% and the stock eventually trading on a P/E of 12.0x, using a 6.98% to 7.0% discount rate and assuming the share count holds steady.
• On this view, current pricing already asks a lot of the company, so any shortfall against guidance on revenue, margins or Phibro Forward execution could justify a lower share price closer to that US$38.00 narrative fair value.

Whichever version feels closer to how you see Phibro Animal Health, the key is to line up the numbers that need to be true for that story to hold and decide whether the current US$43.16 share price leaves enough room for the kind of outcome you think is most realistic.

To see how these bullish and bearish narratives evolve as new earnings, guidance and management updates come through, and to weigh how the balance of risks and rewards is shifting, it helps to track them in one place alongside the live share price and valuation checks. You can do this through the community narratives and your own watchlist tools.

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Phibro Animal Health on Simply Wall St. Add the company to your watchlist or portfolio so you’ll be alerted when the story evolves.

Do you think there’s more to the story for Phibro Animal Health? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com